MX2016013741A - Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson. - Google Patents

Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.

Info

Publication number
MX2016013741A
MX2016013741A MX2016013741A MX2016013741A MX2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A
Authority
MX
Mexico
Prior art keywords
parkinson
patient
disease
rapid relief
motor fluctuations
Prior art date
Application number
MX2016013741A
Other languages
English (en)
Spanish (es)
Inventor
Michael M Lipp
Martin Freed
Richard P Batycky
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of MX2016013741A publication Critical patent/MX2016013741A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2016013741A 2014-04-21 2014-04-21 Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson. MX2016013741A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/034778 WO2015163840A1 (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease

Publications (1)

Publication Number Publication Date
MX2016013741A true MX2016013741A (es) 2017-04-06

Family

ID=54332876

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013741A MX2016013741A (es) 2014-04-21 2014-04-21 Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.

Country Status (14)

Country Link
US (2) US20170296498A1 (enExample)
EP (2) EP3134077A4 (enExample)
JP (1) JP2017513866A (enExample)
KR (2) KR20210144946A (enExample)
CN (2) CN106659685B (enExample)
AU (2) AU2014391721B2 (enExample)
BR (1) BR112016024502A8 (enExample)
CA (1) CA2946165C (enExample)
IL (2) IL309959A (enExample)
MX (1) MX2016013741A (enExample)
RU (1) RU2698330C2 (enExample)
SG (1) SG11201608608PA (enExample)
WO (1) WO2015163840A1 (enExample)
ZA (1) ZA201607833B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
BR112020013749A2 (pt) * 2018-01-05 2020-12-01 Impel Neuropharma, Inc. dispensação intranasal de pó de levodopa por dispositivo olfativo de precisão
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
HUE031167T2 (hu) * 2002-03-20 2017-07-28 Civitas Therapeutics Inc A levodopa pulmonális bejuttatása
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US8496002B2 (en) 2007-06-12 2013-07-30 Civitas Therapeutics, Inc. Powder inhaler devices
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
AU2009265760B2 (en) * 2008-06-30 2013-07-18 Novartis Ag Combinations comprising mGluR modulators for the treatment of parkinson's disease
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
MX390106B (es) * 2012-10-22 2025-03-20 Merz Pharmaceuticals Llc Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use

Also Published As

Publication number Publication date
US20170296498A1 (en) 2017-10-19
RU2698330C2 (ru) 2019-08-26
US20230053976A1 (en) 2023-02-23
CA2946165C (en) 2022-10-18
AU2020239754B2 (en) 2022-06-23
JP2017513866A (ja) 2017-06-01
KR20170008754A (ko) 2017-01-24
RU2016144340A3 (enExample) 2018-05-22
EP3134077A1 (en) 2017-03-01
EP3831375A1 (en) 2021-06-09
KR20210144946A (ko) 2021-11-30
BR112016024502A8 (pt) 2021-06-29
EP3134077A4 (en) 2017-12-20
AU2014391721B2 (en) 2020-07-16
SG11201608608PA (en) 2016-11-29
CA2946165A1 (en) 2015-10-29
ZA201607833B (en) 2018-08-29
CN113209055A (zh) 2021-08-06
RU2016144340A (ru) 2018-05-22
IL309959A (en) 2024-03-01
AU2014391721A1 (en) 2016-11-03
CN106659685B (zh) 2021-02-05
WO2015163840A1 (en) 2015-10-29
AU2020239754A1 (en) 2021-01-14
IL248445A0 (en) 2016-12-29
BR112016024502A2 (pt) 2017-08-15
CN106659685A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
MX2021001091A (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
SA521421115B1 (ar) عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
PH12018501072A1 (en) Modified release orally administered amino acid formulations
MX2015015249A (es) Peptidos terapeuticos.
MX351508B (es) Sistemas y métodos para el diseño y fabricación de calzado de protección de pacientes.
MY179105A (en) Methods of treating alzheimer's disease
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
EA201992832A1 (ru) Подкожное введение adamts13
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
MX2019000677A (es) Células miméticas de células b.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
ZA201704327B (en) Methods and compositions for treating brain diseases
MX367321B (es) Composición para el cuidado de la piel y métodos para la misma.
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
MX2016013741A (es) Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.
WO2014111790A3 (en) Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
MY202857A (en) Method of treating hyperglycemia
HK1235011A1 (en) Rapid relief of motor fluctuations in parkinson's disease
WO2014006571A3 (en) Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof
WO2018026776A3 (en) Foxm1 modulators and uses thereof
TR201903234T4 (tr) Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti.